ClinicalTrials.gg
CompletedNCT07222709Updated Oct 15, 2026

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

A Phase 1 interventional study of ABBV-1042 and Placebo in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Updated Oct 15, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-1042
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Body weight ˃ 45 kg at the time of screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead

Exclusion criteria

Exclusion Criteria:

  • History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
  • Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), , hematological, immunological, neurological, or psychiatric disease that, , in the opinion of the investigator, could compromise either participant safety or the results of the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    ABBV-1042 or Placebo-Group 1

    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

    Drug: ABBV-1042 · Drug: Placebo

  • Experimental
    ABBV-1042 or Placebo-Group 2

    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

    Drug: ABBV-1042 · Drug: Placebo

  • Experimental
    ABBV-1042 or Placebo-Group 3

    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

    Drug: ABBV-1042 · Drug: Placebo

  • Experimental
    ABBV-1042 or Placebo-Group 4

    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

    Drug: ABBV-1042 · Drug: Placebo

  • Experimental
    ABBV-1042 or Placebo-Group 5

    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

    Drug: ABBV-1042 · Drug: Placebo

  • Experimental
    ABBV-1042 or Placebo-Group 6

    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

    Drug: ABBV-1042 · Drug: Placebo

Interventions

  • DrugABBV-1042

    Oral Solution

  • DrugPlacebo

    Oral Solution

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 32 days

  2. Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements

    Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Time frame: Up to approximately 3 days

  3. Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

    Time frame: Up to approximately 3 days

  4. Number of Participants with Abnormal Change in Physical Examinations

    Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed.

    Time frame: Up to approximately 3 days

  5. Number of Participants with Change from Baseline in Electrocardiogram (ECG)

    12-lead resting ECG will be recorded.

    Time frame: Up to approximately 3 days

  6. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed

    Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

    Time frame: Up to approximately 3 days

  7. Maximum Plasma Concentration (Cmax) of ABBV-1042

    Cmax of ABBV-1042

    Time frame: Up to approximately 3 days

  8. Time to Cmax (Tmax) of ABBV-1042

    Tmax of ABBV-1042

    Time frame: Up to approximately 3 days

  9. Apparent terminal phase elimination constant (β) of ABBV-1042

    β of ABBV-1042

    Time frame: Up to approximately 3 days

  10. Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042

    t1/2 of ABBV-1042

    Time frame: Up to approximately 3 days

  11. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042

    AUCt of ABBV-1042

    Time frame: Up to approximately 3 days

  12. Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042

    AUCinf of ABBV-1042

    Time frame: Up to approximately 3 days

07

Study locations

1 site
  • Acpru /Id# 279405
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Sep 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 30, 2025
StartActual
Oct 27, 2025
Primary completionActual
Sep 18, 2026
CompletionActual
Sep 18, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Study completion
Sep 2026→Sep 18, 2026 (actual)
moved 2 times, Oct 8, 2026 – Oct 15, 2026
Enrollment
48→36
Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Study completion Nov 2026→Sep 18, 2026 (now actual)
    Enrollment 48→36
  2. Oct 8, 2026
    Study completion Sep 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07222709
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Oct 27, 2025
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026
Last update
Oct 15, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion